From disease-specific targets to focused therapeutics
Alethia Biotherapeutics is developing innovative therapeutic approaches in areas of unmet medical needs. Alethia is currently focusing on ovarian cancer, on severe bone loss that occurs in metastatic cancer, and on metastatic breast cancer, three indications for which there are very few therapeutic options. Alethia capitalizes on its capacity to identify and validate disease-specific targets for the development of highly focused therapeutics.
News
March 31, 2008
GO Capital and BDC Venture Capital invest in Alethia Biotherapeutics
June 8, 2008
June 14, 2008
Alethia Biotherapeutics is moving to a modern new facility
New address:
141, ave. du Président-Kennedy
Suite SB-5100
Montréal, Québec H2X 1Y4
Events
May 4-6, 2008
Alethia to present data on its ovarian cancer program at the 4th Canadian Conference on Ovarian Cancer Research, Montréal, QC
Mario Filion and Gilles Tremblay will be in attendance.
June 17-20, 2008
Alethia Biotherapeutics Inc. to be part of the Quebec delegation at BIO 2008, San Diego, USA.
Yves Cornellier, Mario Filion and Gilles Tremblay will be in attendance.
Copyright © 2002-2008 Alethia Biotherapeutics Inc. All rights reserved.
Best viewed with Firefox, Internet Explorer 7 and Safari